Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart stent showdown: one branch or two?

NCT ID NCT00376571

Disease control Sponsor: Aarhus University Hospital Skejby Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the best way to use drug-eluting stents (tiny mesh tubes that release medication) in patients with coronary artery disease where the blockage is at a fork (bifurcation). 413 patients were randomly assigned to get stents in both branches of the fork or only in the main branch, with optional treatment of the side branch. The goal was to see which approach reduces the risk of heart-related death, heart attack, stent clotting, or the need for repeat procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
drug-eluting stent
What this could lead to
If successful, this could help doctors choose the safest and most effective stenting strategy for patients with blocked arteries at a fork (bifurcation).
What could go wrong
This is a completed Phase 4 trial with 413 patients, so results are already known. The findings may not apply to all types of blockages or newer stents.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

413 people

The number who actually took part.

Start date

Oct 2004

Finished

Mar 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Stable or unstable AP. * Bifurcation lesion of "LAD/diagonal", "Cx/obtuse marginal", "RCA-PDA/posterolateral branch or LM/Cx/LAD in a right dominant system. * Diameter of main vessel by visual estimate \> 2.5 mm. * Diameter of side branch by visual estimate \> 2.0 mm. * Signed informed consent. Exclusion Criteria: * ST-elevation AMI within 24 hours. * Expected survival \< 1 year. * S-creatinine \> 200 Umol/l. * Allergy to Aspirin, Clopidogrel or Ticlopidine. * Allergy to sirolimus/paclitaxel. * Left main bifurcation in a non-right dominant system.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease

Contacts and locations

Locations

  • Skejby Hospital, University of Aarhus

    Aarhus, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.